Navigation Links
Reed Group Ltd. Announces Enterprise License for New Zealand's Accident Compensation Corporation
Date:9/13/2007

WESTMINSTER, Colo., Sept. 13 /PRNewswire/ -- Reed Group Ltd., publisher of The Medical Disability Advisor (MDA) guidelines and a global leader in return- to-work and disability management products and services, announced today that New Zealand's Accident Compensation Corporation (ACC) has purchased an enterprise license of the MDA. This new agreement will allow ACC to broaden its use of the MDA throughout various government agencies and healthcare organizations in New Zealand.

"Ministry of Social Development has observed the success at ACC since their adoption of the MDA in 1999, reducing absence significantly," according to Dr. David Rankin, Senior Advisor for The Ministry of Social Development. From July 1999 through October 2000, the average number of days per case dropped nearly 50%, attributed in part to implementation of guidelines. "As an integral component of our reform of the Sickness Benefit and Invalid's Benefit in New Zealand, case managers will rely on this tool to refine our return-to- employment systems. The integration of the MDA into case management practice will be fundamental in developing work plans and assisting people into employment."

"New Zealand's success in reducing disability-related absence in the workplace demonstrates the impact of our disability duration guidelines," states Presley Reed, founder and Chief Medical Officer of Reed Group. "Our primary goal is to help people. Reed Group believes that productive endeavor is essential to an individual's well being. In turn, we believe that healthy, timely return to work is as important to the employee as it is to the employer."

The ACC currently uses Reed Group's Data Integration product, which is based on The Medical Disability Advisor, Workplace Guidelines for Disability Durations, Fifth Edition (MDA). The MDA D.I. license provides integrated disability management capabilities for enterprise-wide use, offering real-time access to the contents of Reed Group's disabi
'/>"/>

SOURCE Reed Group Ltd.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Cardinal Health likes growth potential of Viasys NeuroCare Group
2. Technology consulting group adds Sanders
3. CIO Leadership Series: Kathi Christian, QTI Group
4. CEO of healthcare group still hopeful IT will save employers money
5. California group says ruling weakens WARFs stem cell patent
6. Instant messaging comes to groups
7. Midwest plays small role in VC investment, angel groups to the rescue
8. Group promoting classified research elects officers
9. Milwaukee regional development group agrees on name
10. Local group building Dane County economic development corp.
11. Bruker AXS to acquire companies, form Microanalysis Group

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., , NEW YORK, Dec. 1 ...arch report is available in its catalogue: ,, ...ww.reportlinker.com/p0164494/Chromium---Global-Mar...um is primarily influenced by stainless steel, whi...markets is also important for growth of chromium m...
(Date:12/1/2009)..., , CAMBRIDGE, Mass., Dec. 1 /PRNew...c biology industry and to promote its potential, a...formation of the Synthetic Biology Industry Associ...ek. The goal of the association is to provide a fo...scuss the new industry, address its opportunities ...
(Date:12/1/2009)..., , SPRINGFIELD, Ill., Dec. 1 /PRNewswi... is proud to announce that it was recently awarded...Awards event on Nov. 13 in New York City. The CLIO...and innovation in the healthcare advertising indus... the world,s most recognized awards competitions f...
(Date:12/1/2009)... Congruent Software agree...including project accounting clients) to Synergy B... Seattle, WA (PRWEB) Decemb... today it has acquired the Microsoft Dynamics SL p...ness technology provider. The move was necessary d...
Breaking Biology Technology:Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology 2Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3
...Pioneering medical device company Signostics annou...Food and Drug Administration (FDA) for its palm-si... (Photo: http://www.newscom.com/cgi-bin/prnh/2009...t-effective device that for the first time makes i...o use ultrasound in their clinical practice. Just ...
...otek,s Commitment to the Development of Farletuzum...nza,s Ability to Offer Specialty Development and M...Switzerland, May 19 Morphotek(R), Inc., a subsidi...za Group Ltd jointly announced today that they hav...upport the development and manufacturing of a subs...
...utic for IBD with Novel Mode of Action , , MOUNTA...ay announced that data from the company,s PROTECT-...ion in Crohn,s disease Trial) Phase II/III clinica...with moderate-to-severe Crohn,s disease will be pr...gestive Disease Week (DDW) meeting. Traficet-EN i...
Other Biology Technology:Signostics Receives FDA Clearance for World's Smallest Ultrasound Product 2Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 2Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 3Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5
(Date:12/1/2009)...NNYVALE, Calif., Dec. 1 GestureTek...ase 3.0 - a turnkey, portable, plug and play inter...exhibits, entertainment and touring promotions. Ge...atents in camera-enabled gesture recognition techn...tertainment systems. ,, Guaranteed for quality,...
(Date:12/1/2009)..., winner of the 2009 Inserm Grand Prix., Every y... to paying tribute to outstanding,work performed ...talents, Inserm intends to,demonstrate the divers...iological, medical and,health research, and the c...ry out and,drive this research each day. The Inse...
(Date:12/1/2009)...sh. -- Time-lapsed video of individual breast tiss...life of a cell: a protein that cycles between two ...esearchers a more complete view of the internal si...ts that go awry in cancer and are targets of drug ...ls respond to growth factors, travels back and for...
Breaking Biology News(10 mins):GestureTek Unveils The CUBE V3 Portable, Plug and Play Interactive Projection Display System for Advertising and Exhibits 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 2ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 3ERK's got rhythm: Protein that controls cell growth found to cycle in and out of cell nucleus 4Expanding into New Markets with Customer Focused Solutions Orion Health Sees Strong Growth 50233 1Expanding into New Markets with Customer Focused Solutions Orion Health Sees Strong Growth 50233 2Expanding into New Markets with Customer Focused Solutions Orion Health Sees Strong Growth 50233 3Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 4661 1Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 4661 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 4661 3Mice run faster on high grade oil 9038 1Mice run faster on high grade oil 9038 2
...urprising capacity for repair, researchers report ...ished by Cell Press. The novel insight into the br...e clinical implications for the treatment of brain...rchers found that mice whose brains were severely ... in one region just after birth showed substantial...
...Vaccine 1 highlights the huge gap between current ...ndations endorsed by the European Union. Currently...s are receiving seasonal influenza vaccine in Euro...ions and mortality. , For the first time, resear...European public health officials to visualise the ...
...h over the bacterial contamination of spinach, it ...r world would be without the contribution to our f...tic acid-producing bacteria. Researchers from the ...DOE JGI) and the University of California, Davis,...e sequences of nine different lactic acid-producin...
Other Biology News:Neural stem cells lend the brain a surprising capacity for self-repair 2First-time analysis reveals millions of Europeans left at risk from influenza 2First-time analysis reveals millions of Europeans left at risk from influenza 3Genomic comparison of lactic acid bacteria published 2
Rabbit Anti-TAK1, phospho (Thr184 / Thr187) Monoclonal Antibody, Unconjugated, Clone 90C7 from Cell Signaling Technology
Rat Anti-Gamma delta T Lymphocytes Monoclonal Antibody, Unconjugated, Clone MAC320 from BD Biosciences Pharmingen
Rabbit Anti-Human FAK, phospho (Ser843) Antibody, Unconjugated from Upstate
Mouse Anti-DcR1 Monoclonal Antibody, Biotin Conjugated, Clone DJR3 from Abcam
Biology Products: